Hansoh Pharmaceutical Group stock

3692 · HKEX · HKD

$33.90Change from previous close: −1.51%Absolute change: −$0.52

Close · November 16, 2026

Price history

−13.92% over the period

1 year: from $39.38 (November 17, 2025) to $33.90 (November 16, 2026), −13.92%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026$33.90
October 30, 2026$32.36
September 30, 2026$35.30
August 31, 2026$35.34
July 31, 2026$32.18
June 30, 2026$29.62
May 29, 2026$31.44
April 30, 2026$37.10
March 31, 2026$35.48
February 27, 2026$34.96
January 30, 2026$38.60
December 31, 2025$36.08
November 28, 2025$40.22
November 17, 2025$39.38

At a glance

  • The company

    Researches, develops, produces and sells pharmaceutical products for oncology, anti-infection, central nervous system and metabolic diseases in China

  • Latest results

    Quarter to June 30, 2026 · EPS ¥0.70

TickerLandia's take on Hansoh Pharmaceutical Group

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$28.06
52-wk high$44.22

−23.34% from the 52-week high

Analysts · 23 analysts

Average target$48.38+42.72% vs. price

Buy 23 · Hold 0 · Sell 0 · Strong buy

TickerLandia Fingerprint: Hansoh Pharmaceutical Group

Compared with similar companies: very high financial strength and very high profitability.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Hansoh Pharmaceutical Group is cheaper than similar companies

Hansoh Pharmaceutical Group's P/E (trailing 12 months): 28.4, −21% against the median of a group of 11 similar companies (35.9).

Compared with 11 similar companies

Hansoh Pharmaceutical Group's metrics compared with similar companies
MetricHansoh Pharmaceutical GroupPosition in the groupBand
P/E (trailing 12 months)28.4Middle
Forward P/E25.6Middle
Operating margin37.3%High
ROE19.4%Middle
Debt/equity0.11Middle

Grey band: the middle half of the group; tick: the median; dot: Hansoh Pharmaceutical Group. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

¥8.3B

Latest quarter · Q2 2026

Net income

¥4.26B

Latest quarter · Q2 2026

Quarterly net margin

51.3%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$208.68B
P/E
28.4
EPS
$1.21
Volume
6.3M
Daily trading
€46.32M
Dividend yield
1.43%
Last ex-dividend on September 22, 2026

How Hansoh Pharmaceutical Group is changing

All results
  • Revenue grew 11.6% a year on average over the last 5 years

  • Operating margin rose from 27.8% to 35.9%

  • Profits turn into cash: free cash flow equal to 98% of net income

Returns

Hansoh Pharmaceutical Group returns with dividends

$1,000 invested in Hansoh Pharmaceutical Group 5 years ago, on November 16, 2021, would be worth $1,938 today with dividends reinvested: +93.76% in total, +14.15% per year. On price alone it would be $1,817 (+81.67%).

PeriodHansoh Pharmaceutical GroupHang Seng$1,000 becomes
1 month+6.81%−1.79%$1,068
6 months−3.58%−8.96%$964
Year to date−6.04%−7.32%$940
1 year−12.71%−9.97%$873
3 years+145.06%+33.20%$2,451
5 years+93.76%−7.62%$1,938

Over the last 6 months it has done better than 36% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. Hang Seng: price only. Calculate your investment

The chart in detail

Hansoh Pharmaceutical Group: technical analysis

Hansoh Pharmaceutical Group shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 25.4% below its all-time closing high ($45.45, January 22, 2021).

Trend
No clear trend
RSI (14 sessions)
51
Between 30 and 70
vs 200-session average
−0.36%

Support and resistance

Price areas where Hansoh Pharmaceutical Group has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$37.33+10.12%2 touches, last on September 4, 2026
  2. Resistance$36.27+6.99%2 touches, last on September 23, 2026
  3. Resistance$35.16+3.72%7 touches, last on November 5, 2026
  4. Last price$33.90
  5. Support$33.61−0.87%3 touches, last on September 29, 2026
  6. Support$30.76−9.26%6 touches, last on November 3, 2026
  7. Support$28.10−17.11%2 touches, last on June 26, 2026

Volatility and risk

Over the last year it has moved roughly in line with the Hang Seng.

Beta (1 year) vs Hang Seng
0.91
Volatility (60 sessions, annualised)
55.0%
Largest fall in the last year
−34.13%

Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Hansoh Pharmaceutical Group: seasonality

Average monthly price change over 8 years

−0.1%Jan−1.3%Feb+2.3%Mar+3.4%Apr−0.5%May+4.2%Jun+0.7%Jul+2.9%Aug−3.2%Sep−1.0%Oct+6.3%Nov+1.6%Dec

Over the last 8 years, the strongest month for Hansoh Pharmaceutical Group has been November: +6.35% on average, positive in 5 years out of 7. The weakest has been September: −3.18% on average, positive in 4 years out of 8.

Show chart data
MonthAverageMedianPositive years
January−0.12%+6.98%5 of 7
February−1.27%−3.39%3 of 7
March+2.34%−2.77%3 of 7
April+3.40%+4.57%4 of 7
May−0.52%+0.89%4 of 7
June+4.15%+1.62%5 of 7
July+0.66%+1.45%4 of 8
August+2.89%+6.16%6 of 8
September−3.18%0.00%4 of 8
October−0.99%−5.32%1 of 8
November+6.35%+7.33%5 of 7
December+1.55%0.00%3 of 7

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Hansoh Pharmaceutical Group and its competitors

Based in Shanghai and in existence since its founding in 1995, Hansoh Pharmaceutical Group Company Limited develops, makes and sells medicines for the Chinese market, with a portfolio spanning anti-infection drugs, central nervous system treatments, oncology, metabolic diseases and autoimmune conditions. Its product names include Ameile, Hansoh Xinfu, Pulaile, Xintai, Hengmu and XINYUE.

Headquarters
Shanghai, China
Employees
9,643
Founded
1995
Chief executive
Huijuan Zhong
Hansoh Pharmaceutical Group and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Hansoh Pharmaceutical Group3692$26.6B37.3%28.4−3.58%
Divi's LaboratoriesDIVISLAB$32.23B34.0%90.6+63.89%
Torrent PharmaceuticalsTORNTPHARM$18.85B22.2%78.9+6.48%
PharmaEssentia6446$16.42B40.3%59.4+73.91%
Shionogi &4507$16.87B18.6%11.2+5.13%
Jiangsu Hengrui Pharmaceuticals600276$47.82B27.4%35.9−11.06%

Same industry or related industries, similar size. Compare Hansoh Pharmaceutical Group with its competitors · Full profile